MBRX icon

Moleculin Biotech
MBRX

Overview Fund Activity

24 hedge funds and large institutions have $8.57M invested in Moleculin Biotech in 2021 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
24
Holders Change
-7
Holders Change %
-22.58%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
8
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SCM
1
Sio Capital Management
New York
$3.12M
2
Charles Schwab
2
Charles Schwab
California
$61K
3
Geode Capital Management
3
Geode Capital Management
Massachusetts
$736K
4
Vanguard Group
4
Vanguard Group
Pennsylvania
$3.16M
5
MIFH
5
Migdal Insurance & Financial Holdings
Israel
$7K

Top Sellers

1
Citadel Advisors
1
Citadel Advisors
Florida
$0
2
XT
2
XTX Topco
Cayman Islands
$0
3
GCP
3
GSA Capital Partners
United Kingdom
$0
4
Goldman Sachs
4
Goldman Sachs
New York
$0
5
VF
5
Virtu Financial
New York
$0
Name Holding Trade Value Shares
Change 		Shares
Change %
GCP
26
GSA Capital Partners
United Kingdom
– -$114K -2,075 Closed
Goldman Sachs
27
Goldman Sachs
New York
– -$94K -1,714 Closed
VF
28
Virtu Financial
New York
– -$93K -1,687 Closed
WIC
29
Whitegate Investment Counselors
New Hampshire
– -$62K -1,131 Closed
CFO
30
CVA Family Office
Colorado
– -$2K -33 Closed
1
2